

Late-Breaking Research Posters

Exhibit Hall

Note: Abstracts will be posted online by November 10, 2025.

- TH-PO1186** **Randomized Trial of an Early, Standardized Nephrology Consult Triggered by a Machine Learning Model** – Jay L. Koyner, Aiman Fatima, Ola Anjorin, Matthew M. Churpek, ESTOP Investigators
- TH-PO1187** **Preliminary Phase 2 Results of APX-115, a Pan-NOX Inhibitor in Patients with CKD Undergoing Percutaneous Coronary Intervention for Contrast-Induced AKI** – Hyeon-Cheol Gwon, Dae R. Cha, Sung Hwan Moon, Soo Jin Lee, Hyesung Shin
- TH-PO1188** **Effect of Polymyxin B Hemoadsorption on Mortality in Patients with Endotoxic Septic Shock: The TIGRIS Trial** – Javier A. Neyra, Matthieu Legrand, George Tomlinson, John A. Kellum, on behalf of the TIGRIS Investigators
- TH-PO1189** **Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating the Efficacy and Safety of HRS-1780 Tablets in Patients with CKD** – Zhihong Liu, Haitao Zhang, Xiaowei Li, Dongwen Zheng, Guangyu Bi, Zi Ye, Xue Dong, Yuehan Wei, Manchen Bao, Gang Cheng, Rong Huang, Qiuli Dong, Shuai Liu
- TH-PO1190** **Evidence of Kidney Benefit with HTD1801 in Patients with Mild Renal Impairment** – Filip A. Surmont, Leili Gao, Kui Liu, Alexander Liberman, Leigh Macconell, Meng Yu, Liping Liu, Linong Ji, on behalf of the SYMPHONY Investigators
- TH-PO1191** **Comparison of Patients with Primary Hyperoxaluria 1 and Late-Stage CKD from the BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial** – John C. Lieske, Michelle A. Baum, Efrat Benshalom, Vladimir Belostotsky, Felix Knauf, Anne-Laure A. Sellier-Leclerc, Weiming Du, Mary Callanan, Teresa Kauf, Michael D. Murphy, Jaap Groothoff
- TH-PO1192** **Extended-Release Calcifediol (ERC) for Secondary Hyperparathyroidism (SHPT) in Chinese Patients with Stages 3 and 4 CKD: A Phase 3 Trial** – Ming Fang, Haoyan Haoyan, Huijuan Mao, Hong Ren, Hongli Lin, Haiming Li
- TH-PO1193** **First-in-Human Study of SK-08, a Novel Soluble Guanylyl Cyclase Activator: Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Potential for CKD** – Ying Du, Hong Zhou
- TH-PO1194** **Going with the FLOW: A Large Registry Study on Semaglutide and the Risk of Kidney Complications in Patients with Early Diabetic Kidney Disease** – Genya Aharon-Hananel, Johannes F. Mann, Alona Aharonovich, Efrat Leopold, Gil Chernin
- TH-PO1195** **Improving Kidney Failure Risk Predictions for Clinical Trials Across CKD Stages 1-4** – Leonid Shpaner, Panayiotis Petousis, Susanne B. Nicholas, Alex Bui, Obidiugwu Duru, Lindsey M. Kornowske, Cami R. Jones, Kenn B. Daratha, Keith C. Norris, Katherine R. Tuttle, Center for Kidney Disease Research, Education, and Hope (CURE-CKD)
- TH-PO1196** **Phase 4, 52-Week, Single-Arm, Post-Marketing Surveillance to Evaluate Safety of Desidustat for Treatment of Anemia in Patients with CKD** – Kevinkumar A. Kansagra, Deven Parmar, Suchi Shah, Prakash Khetan, Hardik K. Shah, Umesh Khanna, Rana G. Singh, Siddharth Mavani

- TH-PO1197 Model-Based Vadadustat Starting Dose Recommendations in Patients with Dialysis-Dependent CKD –**
Kevin Dykstra, James A. Clary, Pamela C. Navarro Gonzales, Jessica K. Roberts
- TH-PO1198 Vitamin D Metabolome (VDM) Profiles After Single and Repeated Doses of Extended-Release Calcifediol (ERC) in Patients on Hemodialysis (HD) –**
Charles W. Bishop, John Choe, Akhtar Ashfaq
- TH-PO1199 Efficacy and Safety of MT1013 vs. Etelcalcetide for Secondary Hyperparathyroidism in Patients on Hemodialysis –**
Linyuan Wang, Ping Zhang, Jianghua Chen, Xiangling Wang, Zhi Yu, Zhian Huang
- TH-PO1200 52-Week Phase 3 Study to Evaluate the Efficacy and Safety of a Novel Iron-Based Phosphate Binder AP301 in Patients on Dialysis with Hyperphosphatemia –**
Li Zuo, Liangying Gan, Guangyu Bi, Jinsheng Xu, Hong Ye, Huijuan Mao, Hou-yong Dai, Pei Wang, Qing Gao, Yuqing Chen, Yi Li, Jiye Huang, Yan Xu, Hong L. Lin, Aimin Zhong, Jiaxiang Ding, Jing Chen, Yanqing Chi, Hui X. Zheng, Bin Liu, Xiaoliang Zhang, Ming Shi, Yuehong Li, Yingxue C. Liu, Gavin G. Xia
- TH-PO1201 Controlled, Randomized Clinical Trial of Personalized Two-Phase Regional Citrate Anticoagulation in Prolonged Intermittent Kidney Replacement Therapy –**
Qi Zhang, Xiao Bi, Jun Ma, Jun Xue, Yin Zheng, Chen Yu, Zhuxian Zhu, Jianxin Lu, Leyi Gu, Weiming Zhang, Mingli Zhu, Yining He, Xiaonong Chen, Feng Ding
- TH-PO1202 Reduction in Peritonitis-Related Hospitalization and Catheter Loss with the CloudCath Remote Monitoring System –**
Don E. Williamson, Eric H. Yu, Aly ElBadry, Glenn M. Chertow
- TH-PO1203 Renal Autologous Cell Therapy in Diabetes and CKD –**
Bruce F. Culleton, Emily L. Butler, Ahmed Aqeel, Rachita Prakash, Theodore F. Saad, Arnold L. Silva, Thomas D. Wooldridge, Hongxia Yan, Constance M. Barysaukas, Joseph Stavas, Borut Cizman
- TH-PO1204 Joint Effects of Urine Albumin-to-Creatinine Ratio (UACR) and eGFR on Efficacy and Safety with Simultaneous Initiation of Finerenone and an SGLT2 Inhibitor in the CONFIDENCE Trial –**
Amy K. Mottl, Charlie Scott, Li Li, Rajiv Agarwal
- TH-PO1205 Multimodal Kidney Mechanisms of SGLT2 Inhibition in Patients with Type 1 Diabetes –**
Ye Ji Choi, Petter Bjornstad, Phoom Narongkiatikhun, Anil K. Karihaloo, Pottumarthi V. Prasad, Luping Li, Kalie L. Tommerdahl, Jeffrey B. Hodgins, Antoine Clarke, Cheril L. Clarkson, Patricia E. Ladd, Daniël H. van Raalte, Hiddo J.L. Heerspink, Nan Hee Kim, Robert G. Nelson, Victor G. Puelles, David Cherney, Laura Pyle, Farid H. Mahmud, Matthias Kretzler
- TH-PO1206 Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial –**
Michael Karl Schaeffer, Frank T. Weber, Torsten Hoffmann, Christine Wenzkowski, Sylvia Schell-Mader, Antje Meyer, Stefan Tasler, Katharina Fuchs, Kevin Carroll, Tobias B. Huber
- TH-PO1207 Urinary Proteomic Changes Associated with a Healthier Kidney Phenotype After Dapagliflozin Therapy in Adolescent Patients with Type 1 Diabetes –**
Hailey E. Hampson, Kalie L. Tommerdahl, Farid H. Mahmud, Anil K. Karihaloo, Antoine Clarke, Ye Ji Choi, David Cherney, Hiddo J.L. Heerspink, Phoom Narongkiatikhun, Cheril L. Clarkson, Petter Bjornstad, Laura Pyle
- TH-PO1208 Cardiovascular Risk Prediction Modelling with Semaglutide in Patients with Type 1 Diabetes –**
Massimo Nardone, Melissa-Rosina Pasqua, Michael A. Tsoukas, Luxcia Kugathasan, Vikas Sridhar, Marcel Musket, David Cherney, Ahmad Haidar

- TH-PO1209 Vertical Sleeve Gastrectomy Reprograms Endothelial, Tubular, and Immune Compartments in Youth-Onset Diabetic Kidney Disease** – [Long Yuan](#), Ye Ji Choi, Abhijit S. Naik, Fadhl Alakwaa, Kristen Nadeau, Kalie L. Tommerdahl, Hailey E. Hampson, Jesse A. Goodrich, Phoom Narongkiatikhun, Daniël H. van Raalte, Laura Pyle, Matthias Kretzler, Petter Bjornstad
- TH-PO1210 Progression of Cardio-Kidney-Metabolic Syndrome in Adolescents with Type 2 Diabetes** – [Laura Pyle](#), Jairo Arturo Pinzon Cortes, Ye Ji Choi, Phoom Narongkiatikhun, Anil K. Karihaloo, Nisha Bansal, Jenny E. Kanter, Karin Bornfeldt, Katherine R. Tuttle, Ian de Boer, Kumar Sharma, Sushrut S. Waikar, Daniël H. van Raalte, Rose Gubitosi-Klug, Kalie L. Tommerdahl, Petter Bjornstad
- TH-PO1211 Effect of Plant-Based Diet on BP and Gut Microbiota in Kidney Transplant Recipients (PLANET-KT)** – [Rungthiwa Kitpermkiat](#), Ekamol Tantisattamo, Sunchai Payungporn, Prapimporn C. Shantavasinkul, Sansanee Thotsiri, Irin Jariyayothin, Surasak Kantachuesiri, Transplant Coordination Team, the Ramathibodi Excellence Center for Organ Transplantation
- TH-PO1212 Relationship of Albuminuria and Renal Artery Stent Outcomes: Results from the FAIR Randomized Clinical Trial** – [Yuxi Li](#), Fu De Zhou, Beining Wang, Rujie Zheng, Yan Zhang, Jianping Li, FAIR Investigators
- TH-PO1213 PHYOX8: Nedosiran in Pediatric Patients with Primary Hyperoxaluria** – [David J. Sas](#), Sevcan A. Bakkaloglu, Vladimir Belostotsky, María Gema Ariceta Iraola, Gesa Schalk, Loai A. Eid, Jing Yu, Jyoti Arora
- TH-PO1214 Vonafexor in Progressive Alport Syndrome: Early Evidence of Kidney Function Benefit from the ALPESTRIA-1 Trial** – [Bertrand Knebelmann](#), Víctor Martínez Jimenez, Arnold L. Silva, Ankit Mehta, Eric L. Wallace, James F. Simon, Anjay Rastogi, María Vanessa Pérez Gómez, Roser Torra, Suneel M. Udani, Claire Rigothier, Moglie Le Quintrec, Myles Wolf, Jacky Vonderscher, Hugo Girma, Pietro Scalfaro
- TH-PO1215 Short-Term Effects of an SGLT2 Inhibitor on Divalent Ions in Patients with ADPKD: The SIDIA Trial** – [Lorena Roth](#), Dusan Harmacek, Thomas Schachtner, Britta George, Cornelia Hofmann, Argyrios D. Georgalis, Reto M. Venzin, Patrick Hofmann, Thomas Fehr
- TH-PO1216 Linking von Hippel-Lindau Disease and SETD2 in a Common Oncogenic Pathway That Converges on the Mitotic Spindle** – [Manga Motrapu](#), Pratim Chowdhury, Sung Yun Jung, Xiaoli Wang, Ashley G. Boice, Ian J. Frew, Ruhee Dere, Dere Lab
- TH-PO1217 Multicenter, Randomized Phase 2 Study Evaluating the Efficacy and Safety of HRS-5965 in Patients with Primary IgAN** – [Jicheng Lv](#), Yan Zha, Shuxin Liu, Dongwen Zheng, Rui Yan, Zengyan Li, Yinan Li, Sheng Qi, Yanfang Zou, Kaiyun Zhang, Chang Shu, Rong Huang, Liuchao Zhang, Hong Zhang
- TH-PO1218 Kidney Function Preservation with Belimumab in Patients with Lupus Nephritis Receiving Mycophenolate Mofetil (MMF) Standard Therapy in the BLISS-LN Trial: Improved Proteinuria, Clinical Outcomes, and Biomarkers for Belimumab vs. Placebo** – [Brad Rovin](#), Hans J. Anders, George Bertias, Ana Delgado, Roger Abramino Levy, Paula S. Curtis, Ciara O'Shea, Ryan Tomlinson, Richard Furie
- TH-PO1219 Patients (Pts) with FSGS Reach Proteinuria <0.7 g/g More Often with Sparsentan (SPAR) vs. Irbesartan (IRB) in DUPLEX: Implications for Kidney Failure (KF) Risk** – [Jai Radhakrishnan](#), Daniel P. Gale, Rasheed A. Gbadegesin, Julia K. Inrig, Radko Komers, Alex Mercer, Edward Murphy, David Pitcher, Moin A. Saleem
- TH-PO1220 Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab (OBI) in Treatment of Immunosuppression-Resistant Primary FSGS, or Contraindication to High-Dose Steroids: A Two-Year Study** – [Ladan Zand](#), Eddie L. Greene, Wisit Cheungpasitporn, Maria J. Vargas-Brochero, Sanjeev Sethi, Pierre M. Ronco, Fernando C. Fervenza

- TH-PO1221 Unmasking the Role of Antinephrin Antibodies in FSGS Recurrence After Transplantation: A Multicenter Study from the TANGO Consortium** – [Marie-Camille Lafargue](#), Frank E. Hullekes, Rucháma Verhoeff, Christian Leguern, Paolo Cravedi, Leonardo V. Riella, TANGO Consortium
- TH-PO1222 Acute Dip in eGFR in Patients Treated with Tirzepatide: A Post Hoc Analysis of Long-Term Clinical Trials of Tirzepatide Treatment** – [Bruno Linetzky](#), Adam Stefanski, Irina Jouravskaya, Dachuang Cao, Russell J. Wiese, Ryan Griffin, Imre Pavo, Hiddo J.L. Heerspink
- TH-PO1223 Population Pharmacokinetic and Exposure-Response Modeling Supports BI 764198 20 mg as the Therapeutic Dose for Phase 3, with No Dose Adjustment Required** – [Silke Retlich](#), Hendrik M. Lagraauw, Klas J. Petersson, Undine Falkenhagen, Alexander Voelkner, Nima Soleymanlou, Maximilian T. Lobmeyer, Srinivasa Prasad, Howard Trachtman, Lisa Bungert
- TH-PO1224 Dd-cfDNA Predicts Long-Term Graft Outcomes: Kidney Allograft Outcomes AlloSure Registry (KOAR) Results** – [David Wojciechowski](#), Tarek Alhamad, Dhiren Kumar, Jeffrey A. Klein, Peale Chuang, Edmund Huang, Kalathil K. Sureshkumar, Christopher Lawrence, Renata Ponsirenas, Ling Shen, Robert Woodward, Thin Thin Maw, Alexander C. Wiseman, Daniel C. Brennan, KOAR Principal Investigators
- TH-PO1225 Dapagliflozin Treatment Induces Alternate RAAS Activation in Stable Kidney Transplant Recipients** – [Tarik Shoumariyeh](#), Oliver Helk, Vikas Sridhar, Luxcia Kugathasan, Oliver Domenig, David Cherney, Johannes J. Kovarik, Sunita K. Singh, Chantal M. Kopecky
- TH-PO1226 Molecular Diagnostics to Facilitate Belatacept Monotherapy in Kidney Transplant Recipients** – [David Wojciechowski](#), Cyrus Feizpour, Morgan Marsh, Hwarang S. Han, Swee-Ling Levea, Juan D. Salcedo Betancourt
- TH-PO1227 Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial** – [David Wojciechowski](#), Abdolreza Haririan, William S. Asch, Darshana M. Dadhania, Clifton E. Kew, Martha Pavlakis, Kevin J. Fowler, Juergen Beck, Nadiesda Costa
- TH-PO1228 Patient BK Polyomavirus VP1 Genotyping Predicts Neutralizing Antibody Incompatibility and Provides Guardrails for VP1-Targeting Monoclonal Antibody Trial and Therapy** – [Ali Munawar](#), Onno Akkermans, Cristina Úbeda Nicolau, Asanga Bandara, Consuelo Beatriz Correa Sierra, Fernando H. Martins, Steff De Graef, Erin E. Deans, Stephen Ross, Senne Sienaert, Miriam Galindo Cerrada, Vipul C. Chitalia, Nagraj Mani, Stephen D. Weeks
- TH-PO1229 Effects of Sodium-Free Chloride Supplementation on Cardiorenal Function in Chronic Heart Failure** – [Zachary L. Cox](#), Veena Rao, Juan B. Ivey-Miranda, Julieta Moreno Villagómez, Daniela Ramos-Mastache, Jeffrey M. Testani